v3.20.1

Related parties - Narrative (Details) € / shares in Units, $ in Millions |  |  |  |  |  | 12 Months Ended
--- | --- | --- | --- | --- | --- | ---
Nov. 06, 2019 EUR (€) | Oct. 22, 2019 | Aug. 28, 2019 | Aug. 23, 2019 USD ($) item | Aug. 23, 2019 EUR (€) item | Jul. 14, 2019 USD ($) | Jul. 14, 2019 EUR (€) | Dec. 31, 2019 EUR (€) EquityInstruments employee € / shares | Dec. 31, 2018 EUR (€) EquityInstruments € / shares | Dec. 31, 2017 EUR (€) EquityInstruments € / shares
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Number of executive committee members | employee |  |  |  |  |  |  |  | 5 |  |
Number of board of directors | employee |  |  |  |  |  |  |  | 8 |  |
Granted during the period | EquityInstruments |  |  |  |  |  |  |  | 1,699,690 | 1,235,245 | 873,000
Exercise price of warrants | € / shares |  |  |  |  |  |  |  | € 95.1 | € 79.9 | € 77.5
Development milestone amount receivable |  |  |  |  |  |  |  | € 18,200,000 |  |
Cross charges payable relating to development of Filgotinib |  |  |  |  |  |  |  | 30,900,000 |  |
Sales and marketing expenses |  |  |  |  |  |  |  | 8,200,000 |  |
Upfront payment received |  |  |  | $ 3,950 | € 3,569,800,000 |  |  |  |  |
Deferred income classified as current |  |  |  |  |  |  |  | 414,298,000 | € 149,801,000 | € 122,544,000
Total transaction price |  |  |  |  |  |  |  | 3,655,000,000 |  |
Number of performance obligations | item |  |  |  | 3 | 3 |  |  |  |  |
Revenue from contracts with customers related to glpg1690 |  |  |  |  |  |  |  | 17,700,000 |  |
Total impact on revenue |  |  |  |  |  |  |  | 41,000,000 |  |
Sales and marketing expense |  |  |  |  |  |  |  | € 24,577,000 | € 4,146,000 | € 2,803,000
Cost share mechanism |  |  |  |  |  |  |  | 50.00% |  |
Number of outstanding performance Obligations |  |  |  |  |  |  |  | 2 |  |
Restricted Stock Units (RSUs) |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Granted during the period | EquityInstruments |  |  |  |  |  |  |  | 183,450 |  |
Gilead |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Transaction price allocated to remaining performance obligations |  |  |  |  |  |  |  | € 3,593,376,000 |  |
Gilead collaboration agreement for drug discovery platform |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Deferred Income |  |  |  |  |  |  |  | 2,200,000,000 |  |
Revenue from performance obligations satisfied or partially satisfied in previous periods |  |  |  |  |  |  |  | 81,000,000 |  |
GLPG 1690 License |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Cost reimbursement receivable |  |  |  |  |  |  |  | 13,400,000 |  |
Total transaction price |  |  |  |  |  |  |  | € 667,000,000 |  |
Executive committee members as a group |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Granted during the period |  |  |  |  |  |  |  | 315,000 | 350,000 | 475,000
Raj Parekh |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Granted during the period | EquityInstruments |  |  |  |  |  |  |  | 15,000 | 15,000 | 15,000
Harrold van Barlingen |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Granted during the period | EquityInstruments |  |  |  |  |  |  |  |  |  | 7,500
Howard Rowe |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Granted during the period | EquityInstruments |  |  |  |  |  |  |  | 7,500 | 7,500 | 7,500
Werner Cautreels |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Granted during the period | EquityInstruments |  |  |  |  |  |  |  |  | 7,500 | 7,500
Katrine Bosley |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Granted during the period | EquityInstruments |  |  |  |  |  |  |  | 7,500 | 7,500 | 7,500
Christine Mummery |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Granted during the period | EquityInstruments |  |  |  |  |  |  |  |  | 7,500 | 7,500
Mary Kerr |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Granted during the period | EquityInstruments |  |  |  |  |  |  |  | 7,500 | 7,500 | 7,500
Peter Guenter |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Granted during the period | EquityInstruments |  |  |  |  |  |  |  | 7,500 |  |
Gilead |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Possible increase of ownership | 25.10% |  | 22.04% |  |  |  |  | 25.84% |  |
Trade and other receivables |  |  |  |  |  |  |  | € 31,645,000 |  |
Trade and other payables |  |  |  |  |  |  |  | € 39,100,000 |  |
Agreement term (in years) |  |  |  |  |  |  |  | 10 years |  |
Upfront payment received |  |  |  |  |  | $ 3,950 | € 3,600,000,000 |  |  |
Equity investment |  |  |  |  |  | $ 1,100 | € 960,000,000 |  |  |
Deferred Income |  |  |  |  |  |  |  | € 85,600,000 |  |
Current derivative financial assets |  |  |  |  |  |  |  | 85,600,000 |  |
Additional equity investment | € 368,000,000 |  |  |  |  |  |  |  |  |
Line research and development expenditure related to filgotinib |  |  |  |  |  |  |  | € 72,000,000 |  |
Cost share mechanism |  |  |  |  |  |  |  | 50.00% |  |
Gilead | Maximum |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Possible increase of ownership |  | 29.90% |  |  |  |  |  |  |  |
Gilead | GLPG 1690 License |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Cost reimbursements recognized |  |  |  |  |  |  |  | € 17,700,000 |  |
Filgotinib drug license |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Transaction price allocated to remaining performance obligations |  |  |  |  |  |  |  | 780,000,000 |  |
Filgotinib drug license | Gilead |  |  |  |  |  |  |  |  |  |
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] |  |  |  |  |  |  |  |  |  |
Sales and marketing expense |  |  |  |  |  |  |  | € 8,200,000 |  |

X
- Definition The additional equity investment amount. + References No definition available. + Details
Name: | glpg_AdditionalEquityInvestment
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of reimbursement cost receivable from related party. + References No definition available. + Details
Name: | glpg_CostReimbursementReceivable
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of cost reimbursements recognized. + References No definition available. + Details
Name: | glpg_CostReimbursementsRecognized
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition It represents the cost share mechanism for the future development activities, development and sales milestones and royalties. + References No definition available. + Details
Name: | glpg_CostShareForGlobalDevelopmentActivities
Namespace Prefix: | glpg_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of Cross Charges Payable Relating to Development of Filgotinib to related party. + References No definition available. + Details
Name: | glpg_CrossChargesPayableRelatingToDevelopmentOfFilgotinib
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of development milestone amount receivable from related party. + References No definition available. + Details
Name: | glpg_DevelopmentMilestoneReceivable
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of equity investment received as per agreement. + References No definition available. + Details
Name: | glpg_EquityInvestmentReceived
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of the line research and development expenditure recognized. + References No definition available. + Details
Name: | glpg_LineResearchAndDevelopmentExpenditure
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of board of directors. + References No definition available. + Details
Name: | glpg_NumberOfBoardOfDirectors
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of executive committee members. + References No definition available. + Details
Name: | glpg_NumberOfExecutiveCommitteeMembers
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of outstanding performance obligations. + References No definition available. + Details
Name: | glpg_NumberOfOutstandingPerformanceObligations
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of performance obligations. + References No definition available. + Details
Name: | glpg_NumberOfPerformanceObligations
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The term of option, license and collaboration agreement in Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | glpg_OptionLicenseAndCollaborationAgreementTerm
Namespace Prefix: | glpg_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of sales and marketing expenses payable to related party. + References No definition available. + Details
Name: | glpg_SalesAndMarketingExpensesPayable
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of impact on total revenue from the initial and amended filgotinib performance obligation. + References No definition available. + Details
Name: | glpg_TotalImpactOnRevenue
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The total transaction price. + References No definition available. + Details
Name: | glpg_TransactionPriceTotal
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of cash inflow received as upfront payment. + References No definition available. + Details
Name: | glpg_UpfrontPaymentReceived
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amounts payable resulting from related party transactions. [Refer: Related parties [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 24 -IssueDate 2019-01-01 -Paragraph 20 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2019-en-r&anchor=para_20&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 24 -IssueDate 2019-01-01 -Paragraph 18 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2019-en-r&anchor=para_18_b&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_AmountsPayableRelatedPartyTransactions
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amounts receivable resulting from related party transactions. [Refer: Related parties [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 24 -IssueDate 2019-01-01 -Paragraph 20 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2019-en-r&anchor=para_20&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 24 -IssueDate 2019-01-01 -Paragraph 18 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2019-en-r&anchor=para_18_b&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_AmountsReceivableRelatedPartyTransactions
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of current derivative financial assets. [Refer: Derivative financial assets] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 55 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_55&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_CurrentDerivativeFinancialAssets
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of deferred income classified as current. [Refer: Deferred income] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 78 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_78&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DeferredIncomeClassifiedAsCurrent
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2019-01-01 -Paragraph 47 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2019-en-r&anchor=para_47_b&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2019-01-01 -Paragraph 45 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2019-en-r&anchor=para_45&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph 21 -Subparagraph a -Clause iv -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_21_a_iv&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInAssociate
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2019-01-01 -Paragraph 113 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2019-en-r&anchor=para_113_a&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2019-01-01 -Paragraph 114 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2019-en-r&anchor=para_114&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods. [Refer: Performance obligations [member]; Revenue from contracts with customers] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2019-01-01 -Paragraph 116 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2019-en-r&anchor=para_116_c&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of expense relating to the marketing and selling of goods or services. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 85 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_85&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_SalesAndMarketingExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2019-01-01 -Paragraph 120 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2019-en-r&anchor=para_120_a&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2019-01-01 -Paragraph 45 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2019-en-r&anchor=para_45&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
Namespace Prefix: | ifrs-full_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 25 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598 + Details
Name: | us-gaap_DeferredIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=glpg_IfrsRestrictedStockUnitsRsusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_GileadCollaborationAgreementForDrugDiscoveryPlatformMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=glpg_Glpg1690LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=glpg_ExecutiveCommitteeMembersAsGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=glpg_RajParekhMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=glpg_HarroldVanBarlingenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=glpg_HowardRoweMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=glpg_WernerCautreelsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=glpg_KatrineBosleyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=glpg_ChristineMummeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=glpg_MaryKerrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=glpg_PeterGuenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_AssociatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_ResearchAndDevelopmentProgramAxis=glpg_FilgotinibDrugLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |